Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Lung Cancer

  Free Subscription


16.12.2019

1 Ann Thorac Surg
5 Anticancer Res
2 BMC Cancer
1 Cancer
1 Cancer Chemother Pharmacol
1 Cancer Epidemiol Biomarkers Prev
1 Cancer Lett
2 Cancer Sci
2 Chest
1 Eur J Cancer
1 J Cancer Res Clin Oncol
3 J Clin Oncol
4 Lung Cancer
3 Oncogene


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Thorac Surg

  1. MADARIAGA MLL, Troschel Cand Med FM, Best Cand Med TD, Knoll SJ, et al
    Low Thoracic Skeletal Muscle Area Predicts Morbidity after Pneumonectomy for Lung Cancer.
    Ann Thorac Surg. 2019 Dec 7. pii: S0003-4975(19)31830.
    PubMed     Text format     Abstract available


    Anticancer Res

  2. VINAYANUWATTIKUN C, Prakhongcheep O, Tungsukruthai S, Petsri K, et al
    Feasibility Technique of Low-passage In Vitro Drug Sensitivity Testing of Malignant Pleural Effusion from Advanced-stage Non-small Cell Lung Cancer for Prediction of Clinical Outcome.
    Anticancer Res. 2019;39:6981-6988.
    PubMed     Text format     Abstract available

  3. RADES D, Glatzel E, Werner EM, Bohnet S, et al
    Prevalence and Characteristics of Symptomatic Pneumonitis After Radiotherapy of Patients With Locally Advanced Lung Cancer.
    Anticancer Res. 2019;39:6909-6913.
    PubMed     Text format     Abstract available

  4. INOMATA M, Kado T, Okazawa S, Imanishi S, et al
    Peripheral PD1-positive CD4 T-Lymphocyte Count Can Predict Progression-free Survival in Patients With Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor.
    Anticancer Res. 2019;39:6887-6893.
    PubMed     Text format     Abstract available

  5. HASEGAWA T, Yanagitani N, Utsumi H, Wakui H, et al
    Association of High Neutrophil-to-Lymphocyte Ratio With Poor Outcomes of Pembrolizumab Therapy in High-PD-L1-expressing Non-small Cell Lung Cancer.
    Anticancer Res. 2019;39:6851-6857.
    PubMed     Text format     Abstract available

  6. ZINNAH KMA, Park SY
    Duloxetine Enhances TRAIL-mediated Apoptosis via AMPK-mediated Inhibition of Autophagy Flux in Lung Cancer Cells.
    Anticancer Res. 2019;39:6621-6633.
    PubMed     Text format     Abstract available


    BMC Cancer

  7. PALMA DA, Chen H, Bahig H, Gaede S, et al
    Assessment of precision irradiation in early non-small cell lung cancer and interstitial lung disease (ASPIRE-ILD): study protocol for a phase II trial.
    BMC Cancer. 2019;19:1206.
    PubMed     Text format     Abstract available

  8. GE P, Cao L, Chen X, Jing R, et al
    miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer.
    BMC Cancer. 2019;19:1203.
    PubMed     Text format     Abstract available


    Cancer

  9. LI Y, Zang H, Qian G, Owonikoko TK, et al
    ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small-cell lung cancer cells to osimertinib.
    Cancer. 2019 Dec 10. doi: 10.1002/cncr.32655.
    PubMed     Text format     Abstract available


    Cancer Chemother Pharmacol

  10. AGULLO-ORTUNO MT, Garcia-Ruiz I, Diaz-Garcia CV, Enguita AB, et al
    Blood mRNA expression of REV3L and TYMS as potential predictive biomarkers from platinum-based chemotherapy plus pemetrexed in non-small cell lung cancer patients.
    Cancer Chemother Pharmacol. 2019 Dec 12. pii: 10.1007/s00280-019-04008.
    PubMed     Text format     Abstract available


    Cancer Epidemiol Biomarkers Prev

  11. MUSOLF AM, Moiz BA, Sun H, Pikielny CW, et al
    Whole Exome Sequencing of Highly Aggregated Lung Cancer Families Reveals Linked Loci for Increased Cancer Risk on Chromosomes 12q, 7p and 4q.
    Cancer Epidemiol Biomarkers Prev. 2019 Dec 11. pii: 1055-9965.EPI-19-0887.
    PubMed     Text format     Abstract available


    Cancer Lett

  12. LI X, Tong LJ, Ding J, Meng LH, et al
    Corrigendum to "Systematic combination screening reveals synergism between rapamycin and sutent against human lung cancer" [Cancer Letter 342(2014) 159-166].
    Cancer Lett. 2019 Dec 6. pii: S0304-3835(19)30592.
    PubMed     Text format    


    Cancer Sci

  13. SAIGUSA D, Motoike IN, Saito S, Zorzi M, et al
    Impacts of NRF2 Activation in Non-Small-Cell Lung Cancer Cell Lines on Extracellular Metabolites.
    Cancer Sci. 2019 Dec 11. doi: 10.1111/cas.14278.
    PubMed     Text format     Abstract available

  14. LEI L, Wang WX, Zhu YC, Li JL, et al
    The potential mechanism of primary resistance to icotinib in EGFR uncommon mutant advanced non-small cell lung cancer: a multi-center study.
    Cancer Sci. 2019 Dec 11. doi: 10.1111/cas.14277.
    PubMed     Text format     Abstract available


    Chest

  15. SINESHAW HM, Sahar L, Osarogiagbon RU, Flanders WD, et al
    County-Level Variations in Receipt of Surgery for Early-Stage Non-small Cell Lung Cancer in the United States.
    Chest. 2019 Nov 22. pii: S0012-3692(19)33944-3. doi: 10.1016/j.chest.2019.
    PubMed     Text format     Abstract available

  16. MAHAJAN AK, Folch E, Musani A
    Should Interventional Pulmonologists Take Ownership for Ordering Next-Generation Sequencing and Immunohistochemistries for Patients With Newly Diagnosed Non-Small Cell Lung Cancer?
    Chest. 2019;156:1281-1282.
    PubMed     Text format    


    Eur J Cancer

  17. CALIFANO R, Gomes F, Ackermann CJ, Rafee S, et al
    Immune checkpoint blockade for non-small cell lung cancer: What is the role in the special populations?
    Eur J Cancer. 2019;125:1-11.
    PubMed     Text format     Abstract available


    J Cancer Res Clin Oncol

  18. KITADAI R, Okuma Y, Hakozaki T, Hosomi Y, et al
    The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases.
    J Cancer Res Clin Oncol. 2019 Dec 11. pii: 10.1007/s00432-019-03104.
    PubMed     Text format     Abstract available


    J Clin Oncol

  19. SCHNEIDER BJ, Ismaila N, Aerts J, Chiles C, et al
    Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline.
    J Clin Oncol. 2019 Dec 12:JCO1902748. doi: 10.1200/JCO.19.02748.
    PubMed     Text format     Abstract available

  20. PILLAI RN, Fennell DA, Kovcin V, Ciuleanu TE, et al
    Randomized Phase III Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, With Docetaxel Versus Docetaxel in Advanced Non-Small-Cell Lung Cancer (GALAXY-2).
    J Clin Oncol. 2019 Dec 12:JCO1900816. doi: 10.1200/JCO.19.00816.
    PubMed     Text format     Abstract available

  21. CHO JH, Lim SH, An HJ, Kim KH, et al
    Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09).
    J Clin Oncol. 2019 Dec 11:JCO1900931. doi: 10.1200/JCO.19.00931.
    PubMed     Text format     Abstract available


    Lung Cancer

  22. MOLDAVER D, Hurry M, Evans WK, Cheema PK, et al
    Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model.
    Lung Cancer. 2019;139:185-194.
    PubMed     Text format     Abstract available

  23. NAKAGAWA K, Hida T, Nokihara H, Morise M, et al
    Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.
    Lung Cancer. 2019;139:195-199.
    PubMed     Text format     Abstract available

  24. BLOM EF, Ten Haaf K, de Koning HJ
    Trends in lung cancer risk and screening eligibility affect overdiagnosis estimates.
    Lung Cancer. 2019;139:200-206.
    PubMed     Text format     Abstract available

  25. TAN AC, Lai GGY, Tan GS, Poon SY, et al
    Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Lung Cancer. 2019;139:207-215.
    PubMed     Text format     Abstract available


    Oncogene

  26. MARTIN-PADRON J, Boyero L, Rodriguez MI, Andrades A, et al
    Plakophilin 1 enhances MYC translation, promoting squamous cell lung cancer.
    Oncogene. 2019 Dec 10. pii: 10.1038/s41388-019-1129.
    PubMed     Text format     Abstract available

  27. JIN Y, Bao H, Le X, Fan X, et al
    Correction: Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation.
    Oncogene. 2019 Dec 12. pii: 10.1038/s41388-019-1143.
    PubMed     Text format     Abstract available

  28. SEMBA S, Trapasso F, Fabbri M, McCorkell KA, et al
    Correction: Fhit modulation of the Akt-survivin pathway in lung cancer cells: Fhit-tyrosine 114 (Y114) is essential.
    Oncogene. 2019 Dec 9. pii: 10.1038/s41388-019-1130.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: